Showing results (201-210 of 585) with videos related to
Sort By:
Pageof 59
Oncogene|October 12, 2010
Srg3, a mouse homolog of BAF155, is a novel p53 target and acts as a tumor suppressor by modulating p21(WAF1/CIP1) expressionJ Ahn, M Ko, C Lee, et al.Gynecologic Oncology|May 14, 2020
Knowledge of endometrial cancer risk factors in a general gynecologic populationChristina R Washington, Ashley Haggerty, Wanda Ronner, et al.International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|July 24, 2018
Use of Aggressive Surveillance for Locoregional Endometrial Cancer After Local TherapyPratyusha Yalamanchi, Jacob E Shabason, Xiaochen Zhang, et al.Current Computer-Aided Drug Design|January 17, 2012
Computational modeling methods for QSAR studies on HIV-1 integrase inhibitors (2005-2010)Gene M Ko, A Srinivas Reddy, Rajni Garg, et al.Frontiers in Immunology|March 15, 2018
Role of TFH Cells in Promoting T Helper 17-Induced NeuroinflammationJames L Quinn, Gaurav Kumar, Agnieshka Agasing, et al.Gynecologic Oncology|October 8, 2013
Clinical risk factors of PEGylated liposomal doxorubicin induced palmar plantar erythrodysesthesia in recurrent ovarian cancer patientsEmily M Ko, Quinn Lippmann, Whitney P Caron, et al.Journal of Chemical Information and Modeling|October 8, 2010
Computational analysis of HIV-1 protease protein binding pocketsGene M Ko, A Srinivas Reddy, Sunil Kumar, et al.Skeletal Radiology|October 27, 2020
Quantitative assessment of change in upper extremity muscle stiffness following fluid injection using shear wave elastographyO Kenechi Nwawka, Nicholas Gutierrez, Bin Lin, et al.International Journal of Radiation Biology|July 16, 2005
Neoplastic transformation in vitro induced by low doses of 232 MeV protonsE Elmore, X-Y Lao, M Ko, et al.Gynecologic Oncology Reports|February 23, 2024
Prior authorization for FDA-approved PARP inhibitors in ovarian cancerAnna Jo Bodurtha Smith, Annie Apple, Audra Hugo, et al.Pageof 59